Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ialuxid is a consumer health topical gel marketed by Gynial, primarily composed of hydrogen peroxide, hyaluronic acid (sodium hyaluronate), and glycine. It is designed for the treatment of skin and mucosal infections, including those in the genital and vaginal areas. Hydrogen peroxide acts as a broad-spectrum oxidizing antiseptic that eliminates bacteria, fungi, and viruses by inducing oxidative stress. Hyaluronic acid serves as a humectant and biological signaling molecule that promotes tissue regeneration and maintains mucosal moisture, while glycine supports the structural integrity of the skin and mucosa during the healing process. In the context of Gynial's portfolio, it is utilized for managing localized skin or mucosal conditions such as folliculitis, impetigo, or molluscum contagiosum in the genital region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ialuxid.